The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Human biliverdin reductase: A member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity
Open accessAbstract
We describe here the tyrosine kinase activity of human biliverdin reductase (BVR) and its potential role in the insulin-signaling pathway. BVR is both a substrate for insulin receptor (IR) tyrosine kinase (IRK) activity and a kinase for serine phosphorylation of IR substrate 1 (IRS-1). Our previous studies have revealed serine/threonine kinase activity of BVR. Y 198 , in the YMKM motif found in the C-terminal domain of BVR, is shown to be a substrate for insulin-activated IRK. This motif in IRS proteins provides a docking site for proteins that contain a Src homology 2 domain. Additionally, Y 228 in the YLSF sequence and Y 291 are IRK substrates; the former sequence provides optimum recognition motif in the tyrosine phosphatase, SHP-1, and for SHC (Src homology 2 domain containing transfroming protein 1). BVR autophosphorylates N-terminal tyrosines Y 72 and Y 83 . Serine residues in IRS-1 are targets for BVR phosphorylation, and point mutation of serine residues in the kinase domain of the reductase inhibits phosphotransferase activity. Because tyrosine phosphorylation of IRS-1 activates the insulin signaling pathway and serine phosphorylation of IRS-1 blocks insulin action, our findings that insulin increases BVR tyrosine phosphorylation and that there is an increase in glucose uptake in response to insulin when expression of BVR is “knocked down” by small interfering RNA suggest a potential role for BVR in the insulin signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein modules and signalling networks
Pawson, T. (1995) · Nature · doi:10.1038/373573a0 · Cited by 2,420
SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2
Rui, L., Yuan, M., Frantz, D., Shoelson, S., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200444200 · Cited by 904
Cited by
Bilirubin and glutathione have complementary antioxidant and cytoprotective roles
Sedlak, T. W., Saleh, M., Higginson, D. S., Paul, B. D., Juluri, K. R., & Snyder, S. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813132106 · Cited by 530
Heme oxygenase–1, oxidation, inflammation, and atherosclerosis
Araujo, J. A., Zhang, M., & Yin, F. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00119 · Cited by 443
“For instance, BVR has been shown to be a member of the insulin receptor substrate family (Lerner-Marmarosh et al., 2005) with pleiotropic functions that include effects on metabolism and cytoprotection (Kapitulnik and Maines, 2009).”
BackgroundThe Role of Bilirubin in Diabetes, Metabolic Syndrome, and Cardiovascular Diseases
Vítek, L. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00055 · Cited by 311
Heme Oxygenase-1 and the Vascular Bed: From Molecular Mechanisms to Therapeutic Opportunities
Loboda, A., Jazwa, A., Grochot-Przeczek, A., Rutkowski, A. J., Cisowski, J., Agarwal, A., Jozkowicz, A., & Dulak, J. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2043 · Cited by 265
Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Vitek, L., & Ostrow, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789058237 · Cited by 252
Metadata
- Authors
- Lerner-Marmarosh, N., Shen, J., Torno, M. D., Kravets, A., Hu, Z., & Maines, M. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-05-03
- Volume
- 102
- Issue
- 20
- Pages
- 7109-7114
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2105729793
- Cited by
- 158
- References
- 2
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.